Abstracts tagged "ANCA"

Abstract Number: 814 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
Cécile-Audrey Durel¹, Arnaud Hot², Ludovic Trefond³, Olivier Aumaître⁴, Grégory Pugnet⁵, Maxime Samson⁶, Sébastien Abad⁷, Alexandre Belot⁸, Claire Blanchard-Delaunay⁹, Pascal Cathebras¹⁰, Pascal Cohen¹¹, Fleur Cohen¹², Vincent Cottin¹³, Bruno Crestani¹⁴, Stéphanie Dumonteil¹⁵, Claire de Moreuil¹⁶, Stéphane Durupt¹⁷, Jean-Gabriel Fuzibet¹⁸, Margaux Garzaro-regard¹⁹, Nicolas Girszyn²⁰, Bertrand Godeau²¹, Eric Hachulla²², Yvan Jamilloux²³, Patrick Jego²⁴, Estibaliz Lazaro²⁵, Thomas Le Gallou²⁶, Eric Liozon²⁷, Thierry Martin²⁸, Thomas Papo²⁹, Antoinette Perlat²⁶, Pascal Pillet³⁰, Karim Sacre³¹, Pascal Sève³², Loïc Guillevin for the French Vasculitis Study Group³³ and Benjamin Terrier¹¹, ¹Internal Medicine, Hôpital Edouard Herriot, lyon, France, ²Internal Medicine, Hopital Edouard Herriot, Lyon, France, ³Internal medicine, CHU Gabriel-Montpied, clermont-ferrand, France, ⁴CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁵Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, ⁶Dijon University Hospital, Dijon, France, ⁷Internal medicine, Hôpital Avicennes, avicennes, France, ⁸Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁹Internal Medicine, Centre Hospitalier, Niort, France, ¹⁰Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹¹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹²Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹³Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ¹⁴Pneumologie A, Hôpital Bichat - Claude Bernard, Paris, France, ¹⁵Internal medicine, CHU de Limoges, Limoges, France, ¹⁶CHU de Brest, Brest, France, ¹⁷Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ¹⁸Internal medicine, Hôpital l'Archet, Nice, France, ¹⁹Internal medicine, CHU de Nice, Nice, France, ²⁰CHU de Rouen, Rouen, France, ²¹Internal medicine, Hôpital Henri-Mondor, Créteil, France, ²²CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²³Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ²⁴Medecine Interne, CHU Rennes, Rennes, France, ²⁵service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁶Internal medicine, CHU de Rennes, Rennes, France, ²⁷Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ²⁸Cnrs UPR9021, Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, IBMC CNRS UPR9021, Strasbourg, France, ²⁹Paris Bichat, Paris, France, ³⁰Paediatrics, Hôpital Pellegrin, University Hospital of Bordeaux, Bordeaux, France, ³¹Department of Internal Medicine, Bichat Hospital, Paris, France, ³²Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ³³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Orbital mass is a rare ophthalmologic manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) that remains a therapeutic challenge. This study aimed to describe…
Abstract Number: 1764 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study
Kevin Byram¹, Joseph F. Solus¹, Quanhu Sheng¹, Yan Guo¹, C Michael Stein¹ and Michelle J. Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: MicroRNAs (miRNAs) are small RNA molecules (~22 nucleotides) that participate in post-transcriptional gene regulation. miRNAs have potential both as biomarkers for diagnosis and prognosis…
Abstract Number: 2936 • 2017 ACR/ARHP Annual Meeting
B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis
Wayel H. Abdulahad¹, Ulrich Specks², Theo Bijma³, Deborah J. Phippard⁴, Fredrick Karnell⁵, Noha Lim⁵, John H. Stone⁶ and Cees G.M. Kallenberg¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Mayo Clinic College of Medicine, Rochester, MN, ³UMCG, Groningen, Netherlands, ⁴3 Bethesda Metro Center,, Suite 400, Bethesda, MD, ⁵Immune Tolerance Network, Bethesda, MD, ⁶Rheumatology Unit, Massachusetts General Hospital, Boston, MA
Background/Purpose: The current study is aimed to assess the effect of B-cell depletion on the distribution of effector T-cell subsets in AAV-patients. Alterations in CD4+…
Abstract Number: 893 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Belimumab in Combination with Azathioprine for Remission Maintenance in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: A Multicenter Randomized, Placebo-Controlled Study
David Jayne¹, Daniel Blockmans², Raashid Luqmani³, Beulah Ji⁴, Yulia Green⁵, Leanne Hall⁶, David Roth⁷ and Peter A. Merkel⁸, ¹Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ³Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴GSK Stockley Park, Uxbridge, United Kingdom, ⁵GSK Stockley Park, Stockley Park, United Kingdom, ⁶GSK Stevenage, Stevenage, United Kingdom, ⁷GSK Collegeville, Collegeville, PA, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, MN
Background/Purpose: GPA (Wegener’s) and MPA are organ- and life-threatening systemic vasculitides characterized by the presence of ANCA-associated vasculitis (AAV), implicating B cells in disease pathogenesis.…
Abstract Number: 1767 • 2017 ACR/ARHP Annual Meeting
The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months
Gunnar Tomasson¹, Antoine G. Sreih², David Cuthbertson³, Simon Carette⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹University of Iceland, Faculty of Medicine, Reykjavik, IS, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Medicine, Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic College of Medicine, Rochester, MN, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Standard management of ANCA-associated vasculitis (AAV) involves treatment with immunosuppressive agents for at least 18 months. Treatment beyond 18 months reduces the rates of…
Abstract Number: 895 • 2017 ACR/ARHP Annual Meeting
Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease Due to Granulomatosis with Polyangiitis in the US from 1995-2014
Zachary S. Wallace¹, Yuqing Zhang², Leo Lu³, John H. Stone⁴ and Hyon K. Choi⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease due to Granulomatosis with Polyangiitis in the US from 1995-2014 Background/Purpose: Granulomatosis with polyangiitis (GPA)…
Abstract Number: 1768 • 2017 ACR/ARHP Annual Meeting
Cocaine and ANCA Associated Vasculitis-like Syndromes – a Case Series
Sujith Subesinghe¹, Sander van Leuven², Leena Yalakki³, Shirish Sangle (Joint First Author)³ and David P. D'Cruz³, ¹Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom, ²Rheumatology, Radboud University, Nijmegen, Netherlands, ³Louise Coote Lupus Unit, Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Cocaine is a potent illicit stimulant and may trigger a ÔpseudovasculitisÕ mimicking idiopathic ANCA vasculitis. We describe the clinical and serological manifestations of patients…
Abstract Number: 896 • 2017 ACR/ARHP Annual Meeting
The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: A Systematic Review and Meta-Analysis
Jennifer Rodrigues¹, David Collister¹, Amy Archer², Kim Cheema³, Paul Alexander⁴, Christian Pagnoux⁵, Lehana Thabane⁴, Peter A. Merkel⁶, David Jayne⁷ and Michael Walsh¹, ¹Nephrology, McMaster University, Hamilton, ON, Canada, ²Rheumatology, Northwestern University, Chicago, IL, ³Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses of ANCA-associated vasculitis (AAV) are associated with death, decreased renal function, and end-stage renal disease. Whether longer-term treatment with glucocorticoids (GC) reduces the…
Abstract Number: 1769 • 2017 ACR/ARHP Annual Meeting
Incidence, Predictors, and Outcome of Diffuse Alveolar Hemorrhage in Patients with MPO-ANCA Positive Microscopic Polyangiitis: A Multi-Center Retrospective Cohort Study
Takashi Kida, Shunya Kaneshita, Takuya Inoue, Amane Nakabayashi, Yuji Kukida, Kazuki Fujioka, Hidetake Nagahara, Makoto Wada, Takahiro Seno, Masataka Kohno and Yutaka Kawahito, Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Background/Purpose: In patients with microscopic polyangiitis (MPA), a variety of pulmonary lesions including diffuse alveolar hemorrhage (DAH), airways disease and interstitial lung disease (ILD) have…
Abstract Number: 16L • 2016 ACR/ARHP Annual Meeting
Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Pascal Cohen³, Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Luc Mouthon²⁰, Loïc Guillevin²¹ and French Vasculitis Study Group, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Internal Medicine, Cochin University Hospital, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹CH Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³CHU Cavale Blanche, Brest, Brest, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹Service de Médecine Interne et Maladies Infectieuses, CHU de Bordeaux, Pessac, France, ²⁰Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

Background/Purpose: Remission of ANCA-associated vasculitides (AAVs) can be induced with combined glucocorticoids and cyclophosphamide or rituximab (RTX) with comparable efficacy.1 RTX superiority to azathioprine was…
Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Matthew D. Cascino¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁶, Cees G.M. Kallenberg⁷, E. William St Clair⁸, Paul A. Monach⁹, John H. Stone¹⁰ and Paul Brunetta¹¹, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Mayo Clinic, Rochester, MN, ³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Duke University Medical Center, Durham, NC, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Genentech, Inc., South San Francisco, CA
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…
Abstract Number: 1952 • 2016 ACR/ARHP Annual Meeting
Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis
Judith Land¹, Lucas L. Lintermans¹, Coen A. Stegeman², Ernesto J. Muñoz-Elías³, Peter Heeringa⁴, Abraham Rutgers¹ and Wayel H. Abdulahad¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Kineta Inc, Seattle, WA, ⁴Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Granulomatosis with polyangiitis (GPA) patients are often treated with immunesuppressives or B cell depleting therapy. While B cells are involved in GPA pathogenesis as…
Abstract Number: 1931 • 2016 ACR/ARHP Annual Meeting
MRI Findings in Granulomatosis with Polyangiitis: Pachymeningitis and Implications in Quality of Life
Violeta Higuera-Ortiz¹, Natllely Ruiz¹, Daniel Carrillo², Abraham Reynoso², Rosa Delia Delgado-Hernández² and Luis F. Flores-Suarez¹, ¹Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Radiology and Molecular Imaging, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico
Background/Purpose: The frequency of CNS involvement in granulomatosis with polyangiitis (GPA) is uncommon (4-18%). Among them, pachymeningitis (PM) has been reported in 0.6-8%. Improvement of…
Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months
Benjamin Terrier¹, Christian Pagnoux², Elodie Perrodeau³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quémeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal¹⁵, Luc Mouthon¹⁵, Philippe Ravaud¹⁶ and Loïc Guillevin¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵CHU Lyon, Lyon, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, Cochin Hospital, Paris, France, ⁸Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹³Internal Medicine, Centre Hospitalier, Niort, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Hôpital Hôtel Dieu, Paris, France
Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…
Abstract Number: 1933 • 2016 ACR/ARHP Annual Meeting
M2 Macrophage Is the Predominant Phenotype in Airways Inflammatory Lesions in Patients with Granulomatosis with Polyangiitis
Alexandre W.S. Souza¹, Mirjan van Timmeren², Jan-Stephan Sanders³, Coen A. Stegeman⁴, Peter Heeringa⁵, Cees G.M. Kallenberg⁶ and Johanna Westra⁶, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²University of Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Macrophages may present two main phenotypes indicated as M1 and M2 under different stimuli. M1- and M2-macrophages have divergent functions that range from enhancement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.